

Index

a

acetaldehyde 36, 218
 – rhodium enolate 103
 – lithium enolate 70, 90, 93, 94, 96, 97, 100
 – scandium enolate 100
 – yttrium enolate 100
 acetate aldol addition/reaction 153, 154,
 156–161, 172, 176, 177, 183, 187–190, 194,
 197, 198, 200, 321, 323, 331
 acetate aldol problem 176, 188, 317
 acetoacetate aldol reaction 323
 acetophenone 68, 340, 342,
 – potassium enolate 65, 66,
 – lithium enolate 89, 90, 276
 – rhodium enolate 104
 – palladium enolate 105
 – gold enolate 106
 – tin enolate 99
 – zinc enolate 108
 – zirconium enolate 101
 2-acylimidazoles 288
 acylsilanes 267, 268
 AD-mix- α 397
 AD-mix- β 397
 aggregation
 – of LDA 32
 – of enolates 83, 89, 90, 93, 96, 100, 150,
 – peheromone 197
 aklavinone 395
 aldehyde enolates 13, 50, 330
 alkannin 157, 158
 allylic strain 29–31, 177
 $\alpha 7$ nicotinic receptor agonist AR-R17779
 157, 159, 160
 α -amino acids 121, 124, 125, 137, 140, 235,
 236–239, 314
 α -damascone 387, 388
 α -fluorinated carboxylic acids 124, 239

α -fluoroketone 281, 287, 404
 α -tocopherol 117
 α, β_3 -integrin antagonist 213, 220, 221
 aluminum enolates 50, 53, 58, 99, 384
 amide enolates 1, 61, 102, 117, 121, 122, 225,
 268, 269, 396
 2-amino-2'-hydroxy-1,1'-binaphthyl 321
 aspidospermine 139
 atorvastatin 157–159
 azodicarboxylates 234, 235, 237, 401, 403

b

benzoylquinidine 404, 405
 β -hydroxy esters 26, 154, 160, 196, 199, 315,
 321, 337, 348, 349,
 β -lactams 206–212, 364, 367, 368
 bicyclic lactams 137, 139
 BINAP
 – in palladium complexes 264, 265,
 271–274, 278, 279, 301, 302, 335, 336, 391
 – in nickel complexes 302, 303,
 – in rhodium complexes 58, 373, 377,
 379–381, 384
 – in silver complexes 403, 404
 BINOL 317
 – doubly lithiated 334
 – in titanium complexes 318, 319, 369
 – in lanthanum-lithium complexes 340
 – in aluminum-lithium complexes 381–383
 – in zinc complexes 341, 350
 – in zirconium complexes 353–355
 – derived phosphoric acid 362
 – activated by tin(IV) chloride 389
 BINOL monomethyl ether 389
 6,6'-dibromo-BINOL 353
 bis-solvated dimer 32, 33, 35
 boron catalysts 514, 315

- boron enolates 44–49, 58, 59, 67, 70, 98, 99, 149, 159, 163, 164, 167, 172, 176, 178, 180, 182, 185, 187, 189, 190, 193, 194, 211, 238, 331, 379
- boron trifluoride 55, 133, 161, 387
- BOX-ligands/catalysts 323, 327, 328, 344, 366, 369, 371, 372
- bromoacetyl oxazolidinones 200
- (–)-burshehennin 241, 242
- butyllithium 13, 14, 15, 17, 23, 24, 25, 28, 43, 63, 70, 86, 120, 124, 131, 136, 141, 142, 144, 155, 199, 209, 211, 220, 221, 263, 266, 274, 340, 379, 386, 387
- C**
- C₂-symmetric 38, 47, 121, 189, 190, 194, 195, 262, 268, 281, 286, 288, 295, 297, 310
- (–)-callipeltoside A 324, 325
- calyculin A 180
- camphor 125, 126, 129, 153, 160, 228, 235, 236, 394
- camphorsulfonic acid 228, 229, 230
- (–)-captopril 144
- carbene ligands 306
- chelation 26, 43, 85, 103, 117, 122, 133, 172, 206, 227, 257, 339, 346, 356
- chiral phosphites 373
- chiral bisphosphoramides 330–332
- chiral phosphoramides 328–332
 - one-phosphoramidate pathway 329
 - two-phosphoramidate pathway 329
- chiral phosphoramidites 281, 373, 376
- 1-chloro-1-nitroso cyclohexane 236
- cholesterol absorption inhibitor
 - (–)-SCH48461 209, 210
- chromium enolates 102, 261
- cis*-1-amino-2-indanol 126, 165
- Claisen condensation 1, 13, 159, Claisen-Ireland rearrangement 3, 103
- Cl–MeO–BIPHEP 265
- computational study 37, 93, 94, 101, 224, 276
- (*S*)-coniine 205
- continuous variation 92
- copper enolates 51, 56, 57, 106, 336, 338, 357
- correlation
 - between enolate configuration and aldol configuration 44, 45, 149, 150, 161, 195, 317, 330, 346, 372
 - between configuration of enolate and Michael-adduct 223
 - between enone conformation and enolate configuration 53
- crossover experiments 292, 293, 326, 354
- cryoscopy 89
- crystal structures 1, 2, 29, 53, 184, 188, 215, 264, 280, 295, 307, 327, 339, 351, 369, 403
 - palladium enolates 4, 104, 105–107
 - alkali amides 32, 36, 43
 - Reformatsky reagent 64, 108
 - rhodium enolate 66
 - nickel enolates 66, 104, 105
 - lithium enolates 83–86, 88–90, 96, 97
 - lithium aldolate 88
 - magnesium enolate 85
 - boron enolate 98
 - aluminum enolate 99
 - scandium enolate 100
 - yttrium enolate 100
 - titanium enolates 101, 102
 - titanium aldolate 102
 - tungsten enolate 102
 - chromium enolate 102
 - manganese enolate 102
 - iron enolate 103
 - zirconium enolate 101
 - copper enolates 106, 107
 - gold enolate 106
 - zinc enolates 108
 - mercury enolate 109
 - silicon enolate 187
- crystallinity 129, 135, 187
- linked BINOL 362, 363, cuprates 55–57, 217, 218
- Curtin–Hammett 35, 93
- cyanthiwiggin F 289, 290
- cyclic tripeptide OF-4949-III 234
- cyclohexanoic ester 33, 34
- cyclohexanone 18, 28, 39, 263, 276, 286, 392
 - enolate 61, 90, 93, 97, 108, 257, 264–266, 277, 399, 400
- d**
- Davies–Liebeskind enolates 143, 144, 188
- Decarboxylation 70, 235, 262, 284, 290, 392, 393
- decarboxylative allylic alkylation 5, 71, 284–299
- 6-deoxy erythronolide B 153
- deracemization 385, 386
- descriptor 3, 4
- detoxinine 157, 158
- deuterated amino acids 142, 143
- DFT (density functional theory) 35, 94, 96, 97, 223, 278, 294, 408
- DHQ (dihydroquinine) 397
- DHQD (dihydroquinidine) 397

- diacetoneglucose 197
 1,3-diaxial interaction/repulsion 28, 29, 150
 diazaborolidine 99, 194, 195, 211, 212
 dibenzyl ketone enolate 88
 dichotomy 187, 216, 217, 228
 dienolates 19, 28, 183, 184, 225, 229, 316,
 318, 319, 322–324, 331, 336, 337, 347,
 387
 diethyl zinc 64, 201, 212, 342, 344, 349, 367,
 368
 difluoro Reformatsky reaction 350–352, 367,
 368
 D- and L-digitoxose 157, 158
 2,5-dimethylborolane 189
 2,6-dimethylphenol 389
 dioxanone 144, 280
 dioxolanone 140, 141, 146, 147, 153, 270
 2,5-diphenylborolane 189
 diphenylprolinol 342, 344
 direct enolization 99, 132, 165
 disaggregation 90, 93, 95
 discodermolide 180–182
 DMPU 22, 23, 25, 26, 29, 30, 33, 34, 43,
 423
 domino reaction 380, 384
 DOSY (diffusion ordered NMR spectroscopy)
 91, 92, 99
 double bond character 2
 doubly deprotonated carboxylic acid 14, 272,
 273
- e**
 endothelin A receptor antagonist 217
 enolate anion 1, 2, 70, 106, 151, 280, 283, 284,
 293
 enolate tautomers
 – O-bound 1–5, 66–68, 69, 71, 83, 96–101,
 103–109, 127, 200, 278, 284, 297, 299,
 300, 305, 335, 336
 – C-bound 1, 4, 5, 64, 66–68, 69, 89, 96, 97,
 99–107, 109, 261, 300, 305, 306, 309, 348,
 349, 366, 368
 – η^3 -bound (oxallyl) 4, 5, 66, 67, 97, 101, 102,
 104, 377, 378, 380, 384
 ephedrine 117, 119, 122, 163, 164, 170, 176,
 228, 385, 387
 (–)-epibatidine 385, 386
 epimerization 115, 135, 147, 165, 168, 177,
 215, 238, 242, 305
 epothilone A 137, 138, 157, 158
 equilibration 277
 – in enolates 15, 19, 35, 44, 55, 61, 104, 290
 ester enolates 3, 13, 14, 22, 28, 30, 62, 69, 83,
 101, 102, 104, 106, 155, 219, 269
- ethyl bromoacetate 347, 350, 366
 ethyl iodoacetate 261, 348
 “Evans-*syn*” diastereomer 167, 172, 173, 174,
 176
 ezetimibe 203, 204
- f**
 ferrocene-based chiral ligands 266
 (+)-ferrugine 310, 311
 4-fluoroacetophenone
 – deprotonation 34, 35
 – lithium enolate 90, 95, 96
 fluvastatin 157, 159
 (+)-frontalin 141
- g**
 galactosamine 204, 205
 γ -amino- β -oxy-butanoic acid (GABOB) 157,
 158
 gingerol 189, 191
 glycines 28, 99, 200, 206, 207, 269, 270
 gold enolate 106
- h**
 half metals 6
 hamigeran B 263, 264
 heterocoupling 240, 406, 407
 heterodimer 36, 43, 85, 86
 heterodimerization 242
 heterotrimer 36, 37, 43, 91
 hexamethylphosphoric triamide (HMPA) 17,
 22, 24, 29, 30, 33, 34, 53, 56, 57, 90, 117–120,
 122, 137, 138, 189, 224, 227, 374
 MoO₅-HMPA-pyridine 18, 189, 229
 histamine H₃ receptor agonist SCH50971
 226
 HMG-CoA reductase inhibitors 157, 159
 homocoupling 240, 241, 406–408
 homodimer 35, 36, 43, 95
 homodimerization 240
 Hünig’s base (diisopropylethylamine) 45–47,
 50, 132, 165, 167, 171, 173, 185, 191, 194,
 404, 406
 hydrogen bonding 339, 360
 (2*S*,3*R*)- and (2*R*,3*S*)-3-hydroxyisoleucine
 196
trans-2,5-(hydroxymethyl)pyrrolidine
- i**
 imidazolidinone 141, 142, 225, 407
 imino difluoro Reformatsky reaction 368
 imino Reformatsky reaction 213, 366, 367
 immolative 115, 143
 indinavir 126, 127

induced stereoselectivity 148, 155, 163, 185, 194, 197, 204, 222
 inner-sphere mechanism 275, 293, 295
 3,3'-iodo-BINOL 320
 (Ipc)₂BCl 190
 (Ipc)₂BOTf 190, 192
 (S)-ipenol 197, 198
 ion triple 33
 ionic character 7
 ionomycin 120, 130, 131, 178,
 IR spectroscopy 100, 102–104, 336, 356, 401
 Ireland's model 28–31, 33, 37, 222
 iron acetyl complex 188, 202
 iron acyl complex 143
 iron enolates 4, 103, 240
 isocyano ester 339, 340
 isopilocarpine 54

j

Job plot 92

k

Kemp's triacid 389
 ketone enolates 13, 14, 29, 63, 68, 100, 155, 237, 241, 284, 286, 389, 404
 – lithium/magnesium 31, 60, 62, 70, 71
 – boron 46
 – tin 99
 – titanium 101
 – zinc 64, 108, 109
 – zirconium 101
 – higher-substituted 61
 khafrefungin 312, 320, 321,
 kinetic control 15–20, 22, 28, 31, 45, 46, 142, 147, 149, 153, 340
 kinetic resolution 265, 267, 283, 295, 341
 kinetic studies 33, 93, 329, 338, 392,

l

lactones 157, 182, 193, 241, 242, 271–273, 276, 278, 280, 437, 377, 385
 – enolates 20, 257, 270, 271, 279, 302, 303
 lanthanum–lithium complex (LLB) 340, 341
 lithium bis(trimethylsilyl)amide (LiHMDS) 12, 13, 15, 17, 18, 22, 24, 27, 28, 32, 33, 35, 36, 125–127, 135, 146, 236, 267–269, 424
 lithium bromide 22, 36, 37, 90, 257, 258, 259
 lithium chloride 17, 35–38, 43, 44, 68, 94, 100, 105, 122–125, 242, 265–269, 271–274, 276–279, 279
 lithium diisopropylamide (LDA) 6, 12, 13–25, 27–36, 44, 70, 85, 86, 90, 92, 117, 119–121, 123–126, 128, 131, 139–142, 145,

155, 156, 159–161, 163, 166, 184, 185, 200, 206–211, 219, 220, 223, 228, 235, 238, 240, 242, 263–265, 271–274, 295, 297, 310, 364, 365, 387, 388, 395, 405, 423
 lithium enolates 2, 6, 14–18, 21, 23–26, 28, 33, 34, 35, 38, 40, 43, 52–54, 57, 59–63, 70, 89–91, 93–97, 99, 100, 103, 105, 118, 122, 126, 130, 137, 141, 142, 146, 149, 150, 153, 155, 159, 160, 165–167, 172, 185, 188, 197, 199, 202, 204, 206, 209, 222–225, 227, 234–236, 240, 257, 259, 262–271, 273, 276–279, 293–295, 297, 305, 309, 310, 364, 383, 385, 389, 394, 395, 404, 423–425
 – calculations 5, 94, 96, 97
 – crystal structures 83–89
 – NMR studies 2, 14, 34–36, 89–92, 95, 96
 – higher substituted 18, 19, 61
 – less substituted 16, 17, 18
 – UV-vis spectroscopy 93
 lithium isopropylcyclohexylamide (LICA) 12, 13, 117
 lithium tetramethylpiperidide (LTMP) 12, 13, 22, 29, 36, 37
 lovastatin 157, 159
 LUMO 151

m

macbecin I 179, 180
 macrolactin A 322, 323
 macrolide RK-397 331, 333
 magnesium enolates 3, 22, 26, 28, 54, 55, 61, 63, 85, 117, 119, 155, 175, 237, 264
 manganese enolates 4, 102, 103
 Marckwald's definition of asymmetric synthesis 6
 maytansine 154, 155
 Meldrum's acid 392
 Menthol 200, 207, 208, 212
 mercury enolates 109
 (E)- and (Z)-methyl crotonate 222
 methyllithium 16, 60, 61, 62, 259, 385, 386, 389, 390
 methylphenidate (ritalin) 182
 2-methylcyclohexanone 15, 16, 17, 70
 2-methyl tetralone 262, 292, 293
 Michael addition 6, 51, 54, 180, 222, 223–226, 299, 369, 372
 mixed aggregate 34–36, 44, 83, 86, 87, 90, 93, 95, 96, 98, 278, 310
 molybdenum enolates 4, 64, 102
 HOMO 151
 monomer 51, 318
 – LDA 33, 35

- enolates 66, 88, 89–96, 98, 99, 100, 101, 105, 150
- MoO₅·pyridine·HMPA 17, 18, 189, 229
- Mukaiyama aldol reaction 67, 152, 153, 163, 183, 184, 187, 311, 313–318, 320, 322–324, 328, 331, 334, 338, 339, 360
- Mukaiyama–Mannich reaction 205, 353–358, 360–363
- Mukaiyama–Michael addition 369, 370, 372
- n**
- N*-acyl oxazolidinones 20, 132, 176, 180, 204, 229, 231–235, 240
- Naproxen amide 386, 387
- N*-benzylphenethylamine 219
- N*-fluorobenzenesulfonimide 239, 406
- nickel enolates 66, 104, 309, 344, 366
- nitroso aldol reaction 398
- nitrosobenzene 398–400, 403, 404
- NMDA-receptor antagonist 142
- N*-methyl-2-pyrrolidinone (NMP) 173, 174, 213, 298
- N*-methylephedrine 163, 351, 352, 367
- NMR spectroscopy 144, 50, 295, 353
 - rhodium enolates 66, 104, 377
 - boron enolates 99, 379
 - lithium enolates 2, 34–36, 89–92, 95, 96
 - silicon enolates 23, 60
 - magnesium enolates 63
 - nickel enolates 66,
 - titanium enolates 66, 101
 - palladium enolates 66, 68, 69, 105
 - molybdenum, tungsten enolates 102
 - zinc enolates 107
 - mercury enolates 109
- NOE 26, 59, 99, 182, 184
- Nomenclature 3, 4
- “Non-Evans-*syn*” diastereomer 172, 173, 174, 202
- Norephedrine 48, 126, 163
- N*-propionyl oxazolidinone 144, 167, 168, 170, 172, 173
- N*-sulfonyloxaziridine 227, 228
- o**
- organocopper reagent 54–57, 216, 372
- outer-sphere mechanism 275, 276–279, 293, 294–298
- oxazaborolidinones 314, 316
- oxazolidinethione 129, 173, 174, 176
- oxidative addition 68, 280, 283, 284, 290, 297, 298, 300, 309, 374, 392
- oxindole 268, 304, 305–307
- oxy-Cope rearrangement 71, 72
- p**
- paclitaxel 353
- palladium enolates 2, 4, 5, 66–71, 104, 106, 280, 284, 297, 299, 300, 305, 306, 335, 336, 357, 385, 391–394, 406, 425
- palladium-catalyzed allylation 262, 263, 265, 267, 268–271, 273, 275–277, 279, 280–282, 284, 294, 300, 374, 375
- palmerolide A 183, 184
- 3-pentanone
 - (Z)- and (E)-silyl enol ethers 314
 - tin enolate 50, 399
 - lithium enolate 22, 37, 86, 91
 - boron enolate 44, 191, 193
- peptide 157, 167, 233, 234, 270, 338, 373
- phenylalanine 126, 168, 176, 235
- 2-phenylcyclohexanone 17, 399
- (–)-*trans*-2-phenylcyclohexanol 207
- phenylglycine 129
- (S)-phenylglycinol 213
- phenylmenthol 222
- (+)-phorboside A 318, 319
- phosphoramidite ligands 281, 373, 376
- PHOX ligands 270, 308
 - *t*-butyl-PHOX 280, 281, 286, 292, 293, 297, 392, 401
 - (CF₃)₃-*t*-Bu-PHOX 292
- π-stacking 241, 327
- pinacolone 28
- pinacolone enolates
 - lithium 83, 85, 87–89, 97
 - sodium 87
 - potassium 65, 83
 - boron 98,
 - rhodium 66, 104
- purine nucleoside phosphorylase inhibitor
- PNP405 135
- podorhizol 54
- potassium bis(trimethylsilyl)amide (KHMDs) 12, 13, 16, 18, 232–236, 340, 341
- potassium enolates 12, 16, 65, 66, 71, 83, 119, 233, 234, 236, 237, 268, 340
- preformed enolates 1, 3, 5, 11, 12, 31, 50, 83, 115, 147, 148, 261, 262, 275, 309, 369
- prolinol (pyrrolidinemethanol) 119, 120, 122, 130, 184, 227, 230
- prostaglandins 56, 58, 376, 382, 383
- pseudoephedrine 122–125, 217, 218
- PYBOX 323, 324, 326, 327, 346, 369, 372

q

- quenching 43, 52, 57, 61, 147, 215, 230, 232, 373, 376,
 – as silicon enolates 16, 17, 23, 24–26, 59, 60, 219, 423–425

r

- R_2 NH effect 13, 43
 racemization 115, 117, 120–122, 125, 126, 128, 135, 143, 147, 227, 228, 232, 234, 236, 263, 266, 271, 286, 305, 389, 392, 404, 406
 reagent control 122, 133, 189, 193, 272, 273, 400
 recovery (of the auxiliary) 115, 117, 125, 129, 139, 153, 157, 160, 165, 169, 170, 171, 182, 189, 194, 201, 204, 205, 236, 239, 394
 reductive elimination 68, 69, 275, 294, 300, 305, 306, 374
 Reformatsky reagent 64, 106, 108, 211–214, 347, 349, 351
 regioisomer 15–17, 19, 55, 61, 62, 229, 267, 280, 282, 285, 289, 300
 regioselectivity 28, 136, 229, 267, 268, 270, 283, 327, 401, 403, 404
 – in enolate formation 11, 15–20, 44, 46, 52, 132, 218, 297, 346, 387
 remote asymmetric induction 176, 178, 182
 rhenium enolates 4, 103
 rhodium enolates 2, 4, 5, 65–67, 103, 104, 347, 377–381, 384, 425
 rhodium-catalyzed allylic alkylation 268, 269

s

- salen complexes 259–261, 338, 348, 398
 samarium enolate 200, 201
 SAMP hydrazine 218
 scandium enolate 100
s-cis conformation 53, 59, 185, 187
 (–)-sedamine 358, 359
 self-regeneration of chirality 140, 141, 146
 shikonin 157, 158
 silicon enolates 7, 145, 151–153, 160, 161, 163, 182–188, 204, 282, 305, 311, 312, 314–317, 321–323, 329, 334, 335, 353, 353–356, 360, 371, 372, 374, 384, 389, 391, 396, 397–402, 407, 408
 2-silyloxyfuran 283, 358
 simple diastereoselectivity 148, 222, 223, 327, 330, 334, 352, 353, 362, 364
 sodium bis(trimethylsilyl)amide (NaHMDS) 12, 13, 25, 26, 126, 128–130, 136, 138, 183, 228–232, 236, 237, 239, 302, 303, 395, 396
 sodium *t*-butoxide 58, 300, 301–304, 306, 382, 384

- solvation 32–36, 43, 83, 85, 88–90, 94, 96, 97, 122, 224
 sparteine 173, 174, 202, 203, 347
 sphingosine 339, 340
 stereoablative 288
 stereodivergence 46, 174, 175, 185, 186, 193, 202, 203, 206, 209, 227, 228, 235, 236, 328, 329
s-trans conformation 52, 53, 185, 187, 216
 sulfinyl acetate 154
 sulfinylimines 206
 sulfonyloxaziridines 220, 228, 394, 395, 396,
 sultams 53, 136, 137, 138, 185, 186–188, 214–216, 218, 236, 237, 404
 swinholide A 192, 193

t

- TADDOL 197, 198, 199, 230, 339, 373, 406, 407
t-butyl acetate 14, 199
 – enolate 2, 14, 197
t-butyl hydroperoxide 349
 tetrahydrolipstatin 157, 158
 tetrahydropyran 35, 125
 tetramer
 – lithium enolates 35, 83, 85, 87–91, 93, 95–97, 150
 – zinc enolates 106–108
 – aldolate 88
 2,2,6,6-tetramethylpiperidine N-oxide (TEMPO) 230
 thermodynamic acidity 11
 thermodynamic control 60, 153, 277
 – in enolate formation 15, 17–20, 22, 29, 45, 47, 61, 125, 280
 thiazolidinethiones 129, 133, 134, 172–176, 202, 203, 344–346
 thioester enolates 3, 5, 12, 22, 45, 47–49, 63, 148, 189, 190, 212, 315, 387, 388
 tin enolates 49, 50, 99, 176–178, 185–187, 259–263, 293, 398, 399, 403, 404
 tin tetrachloride 133, 172
 titanium enolates 50, 51, 66–68, 132–134, 153, 166, 171, 176, 189, 197–200, 202, 225, 226, 230, 231, 406, 407
 titanium tetrachloride 50, 66, 132, 161, 163, 165, 171–173, 187, 203, 235, 240
 Tol-BINAP
 – in palladium complexes 335
 – in silver complexes 338
 – in copper complexes 354, 357, 399
 topicity 122, 141, 147, 161, 188, 191, 220, 237, 293, 294, 301, 327, 328, 342, 354, 368, 369, 392

- *lk*-topicity 121, 155, 166, 364
- *ul*-topicity 166
- transition state models
 - cyclic transition state 29, 33, 151, 152, 175, 314
 - open transition state 33, 133, 151, 152, 160–162, 172, 183, 187, 188, 223, 313, 320, 331, 334
 - six-membered transition state 28, 33, 149, 150, 151, 165, 263, 334
 - seven-membered transition state 294
 - Ireland's transition state 28–31, 33
 - eight-membered transition state 36, 37, 44, 222, 223
 - Zimmerman–Traxler transition state 149, 150, 151, 161, 165, 167, 173, 175, 177, 187, 189, 194, 206–208, 317, 318, 330, 334, 346, 381
 - Mulzer's transition state 151
 - Heathcock's transition state of enolate formation 29, 30
 - Heathcock's transition state of Michael additions 223, 224
 - Kwan–Evans transition state of Michael additions 223, 224
- trifluoroethanol 401, 402
- trigonal bipyramidal 66, 184, 329
- triisopropylbenzenesulfonyl azide (trisyl azide) 232–234
- trimethylamine as additive in deprotonations 16, 17, 22, 24, 33, 35, 46, 48, 61, 163, 164, 168, 170, 175, 194, 196, 424
- triphenylglycol 155–157, 160, 165, 210
- triphenylglycol esters 155–159, 160, 166, 209, 210
- tropinone 43, 310, 311, 424
- Tsuji–Trost reaction 262, 264, 267, 269, 270, 272, 277, 284
- tungsten enolates 5, 64, 65, 102, 425
- tylonolide 153
- u**
- UV–vis spectroscopy 93
- v**
- Valine 126, 167, 228
- w**
- Weinreb amides 128, 134, 168, 170, 173, 182, 344, 348
- y**
- yttrium enolates 100
- z**
- zaragozic acid D 179
- zinc enolates 28, 50, 51, 57, 63–65, 106, 108, 109, 199, 206, 213, 269, 270, 302, 344, 349, 362–364, 366–368, 373, 374–376
- zincophorin 163
- zirconium enolates 1, 100, 101, 166

